-
Company Insights
Innovation and Patenting activity of Kadmon Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kadmon Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Belumosudil Mesylate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belumosudil Mesylate in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belumosudil Mesylate in Refractory Multiple Myeloma Drug Details: Belumosudil mesylate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Belumosudil Mesylate in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belumosudil Mesylate in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belumosudil Mesylate in Relapsed Multiple Myeloma Drug Details: Belumosudil mesylate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Belumosudil Mesylate in Lung Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belumosudil Mesylate in Lung Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belumosudil Mesylate in Lung Transplant Rejection Drug Details: Belumosudil mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-363 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-363 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Lung Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Lung Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Kidney Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Fibrosis - Drugs In Development, 2023’, provides an overview of the Kidney Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...